SCHEMBL11944445

SCHEMBL11944445

COc1ccc(S(=O)(=O)N2CCN(c3cnn(-c4cc(F)cc(F)c4)c(=O)c3OCC3CC3C)CC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 5/20 0.46
▸ NPSR1 Q6W5P4 2/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ PPARG P37231 1/20 0.46
▸ NCOA2 Q15596 1/20 0.46
▸ NCOA1 Q15788 1/20 0.46
▸ NCOA3 Q9Y6Q9 1/20 0.46
▸ LMNA P02545 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ ALDH1A1 P00352 4/20 0.42
▸ MCHR1 Q99705 1/20 0.42
▸ TP53 P04637 1/20 0.41
▸ PKM P14618 2/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ RAB9A P51151 2/20 0.40
▸ NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14899778 0.85 MCHR1 (0.42) NPSR1CYP3A4CYP2C19LMNASMN1; SMN2
SCHEMBL11944470 0.84 POLB (0.43) POLBNPSR1CYP3A4CYP2C19PPARG
SCHEMBL11945444 0.82 MAPT (0.44) POLBNPSR1CYP3A4CYP2C19PPARG
SCHEMBL17057903 0.82 NPBWR1 (0.47) NPSR1ALDH1A1MCHR1NPBWR1
SCHEMBL11944562 0.81 MAPT (0.38) POLBNPSR1CYP3A4CYP2C19PPARG
SCHEMBL11945702 0.81 MAPT (0.35) POLBNPSR1CYP3A4CYP2C19PPARG
SCHEMBL17058088 0.80 ALDH1A1 (0.35) NPSR1CYP3A4CYP2C19LMNATSHR
SCHEMBL11945700 0.80 SMN1; SMN2 (0.40) POLBNPSR1CYP3A4CYP2C19PPARG
SCHEMBL11945455 0.80 MAPT (0.37) POLBNPSR1CYP3A4CYP2C19PPARG
SCHEMBL11945397 0.80 MAPT (0.37) POLBNPSR1CYP3A4CYP2C19PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA POLB 1088/4885NPSR1 4251/4885CYP3A4 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback